WorkThe story, in brief
AI is saving pharma billions in manufacturing and back-office work, just not in the lab
Pharma's AI bet backfired. Billions saved in ops and manufacturing. Drug discovery? Still waiting.
The KeyNews take
Why it matters
AI's real-world ROI in pharma contradicts industry hype around drug discovery—the gap between promise and delivery is widening across regulated sectors, signaling a broader reckoning on where AI actually creates value.
The key facts
4 to knowEli Lilly's digital chief confirms AI delivering ROI in manufacturing and back-office operations
Drug discovery remains unprofitable for AI investment despite being the most hyped use case
Gap between AI industry promises and pharma lab reality is widening
Pattern suggests over-rotation toward speculative AI applications in regulated industries
Go to the source
The Decoderthe-decoder.com
Publisher excerpt: Eli Lilly's digital chief admits that, so far, AI is paying off in pharma everywhere except where the industry hyped it most: drug discovery.